| Prev Close | 78.56 |
| Open | 78.33 |
| Day Low/High | 76.61 / 78.58 |
| 52 Wk Low/High | 62.48 / 110.36 |
| Volume | 224.36K |
Incyte Corporation (INCY)
76.61
2.00
2.50
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 219.84B |
| Market Cap | 17.51B |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Biotech Isn't Seeing Much Merger Activity, but Here's a Stock to Like
Dynavax Technologies has inked a supply deal related to a Covid-19 vaccine that could greatly increase its revenue stream.
Amazing Small-Caps, Minimum Wage, An Unhealthy Survey, Trading Nvidia, Chegg
The Russell 2000 has now soared 16% year to date, nearly twice the Nasdaq Composite's 8.5% move.
Is Incyte Ready for a Sustained Turn to the Upside?
Let's check out the charts.
Is It Safe Now? Wall Street Bets on Science, Joy in Metville, Citi's Selloff
Electoral risk remains the monster under the bed, and it only grows as our legislators intentionally choose the blame game over honest cooperation.
Incyte Could Rise Another 15% From Here
Shares of biopharmaceutical manufacturer are close to an upside breakout.
Jim Cramer: 20 Stocks That Are Emblematic of What's Driving the Market
This list is not a buy list but a list of stocks that have been brought to new heights.
Upgrades/Downgrades
Amid the sea of news hitting the tape this morning, here's a short list of Upgrades and Downgrades. Upgrades: International Flavors upgraded to Overweight from Equal Weight at Wells Fargo; Target raised to $150 Juniper Networks upgraded to Buy from...
6 Market Winds of Change, Trading Beyond Meat, GrubHub Earnings: Market Recon
If there was not a sizable addressable market for Beyond Meat, the competition would not be building as quickly as it is.
M&A Appetite in Pharma Has Proved Potent: Chart of the Day
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Trading Apple and Netflix, Beyond Meat Earnings: Market Recon
Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.
AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere
The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.
2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land
These two firms have successful drugs and could make nice additions for larger companies.
5 Attractive Ways to Invest in Oncology
Experts offer their top stock ideas in oncology detection and treatment.
Celgene Deal Gets the M&A Ball Rolling in the New Year
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
Interesting Statistics
Some interesting statistics on the day: * Bitcoin is trading at $8.240, for a gain of nearly three percent today. * CNN's Fear and Greed Indicator stands at a neutral 49. * Gold is -$17.70, a drop of -1.4%. * Lumber is -$10, a -2.3% decline. * 3M ...
Who Benefits From Tax Reform?
Technology and biotech companies seem to be among the big winners.
Geron Shares Rise on Fast Track Designation -- Biotech Movers
The FDA granted fast track designation to imetelstat as a potential treatment for adults with with transfusion-dependent anemia.
MacroGenics Soars on Collaboration with Incyte -- Biotech Movers
MacroGenics and Incyte on Wednesday unveiled a collaboration and license agreement regarding MGA012, MacroGenics' investigational monoclonal antibody that inhibits programmed cell death protein 1.
These Stocks Have Changed Direction
Finding bullish and bearish reversals in the market.
Cramer: There Should Be More Takeovers Where These Came From
Buying's good for the acquirers, which should give other companies ideas.
Cramer: Let Loose the Growth Hounds
Day 2 of the selloff brings in an entirely new kind of buyer.
Closing Bell: Stocks End Higher As Corporate Earnings Take Focus
Stocks remained in positive territory breaking a three-day losing streak ahead of U.S. corporate earnings this week, despite mounting tension between North Korea and the U.S.
Takeaways and Observations (3PM Edition)
I started the day with an important piece on bonds - at least I hope so. Sell 'em, short 'em! Trade of the Week - long TBT (consistent with above). Well off the opening, at $37.60 now - and that's a good thing. So far, so good. At 230PM yield...
Stocks That Are Changing Direction
These charts are showing bullish or bearish reversals.
Cramer: Have Faith in International Strength
Because there are other things that will take the wind out of your sails.
